Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 249165
Corporate User License Price USD 10500
Corporate User License Price INR 747495
Site License Price USD 7000
Site License Price INR 498330
Request a Quote

Report Title

t cell surface glycoprotein cd3 epsilon chain (t cell surface antigen t3 leu 4 epsilon chain or cd3e)-pipeline review, h2 2017

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

t cell surface glycoprotein cd3 epsilon chain (t cell surface antigen t3 leu 4 epsilon chain or cd3e)-pipeline review, h2 2017


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

t cell surface glycoprotein cd3 epsilon chain (t cell surface antigen t3 leu 4 epsilon chain or cd3e)-pipeline review, h2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

t cell surface glycoprotein cd3 epsilon chain (t cell surface antigen t3 leu 4 epsilon chain or cd3e)-pipeline review, h2 2017



Executive Summary

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-Pipeline Review, H2 2017

Summary

According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E)-Pipeline Review, H2 2017'; T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation.

The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E)-Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Infectious Disease which include indications Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Hepatitis B, Inflammatory Bowel Disease, Kidney Transplant Rejection, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Psoriasis and Rheumatoid Arthritis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)

-The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects

-The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-Overview 6

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-Companies Involved in Therapeutics Development 20

Amgen Inc 20

GlaxoSmithKline Plc 20

MacroGenics Inc 21

Numab Innovation AG 21

SYNIMMUNE GmbH 22

Tiziana Life Sciences Plc 22

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-Drug Profiles 23

Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

foralumab-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

ND-007-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

otelixizumab-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

TACSYN-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

teplizumab-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

XmAb-13551-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-Dormant Products 34

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)-Product Development Milestones 35

Featured News & Press Releases 35

Jul 28, 2017: Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases 35

Mar 14, 2017: Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board 35

Nov 18, 2016: New Publication: Partial Exhaustion of CD8 T Cells in Responders to Anti-CD3 Treatment in New-Onset Type 1 Diabetes 36

Nov 16, 2016: Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases 36

May 19, 2016: Immunotherapy Journal Review of Anti-CD3 Monoclonal Antibodies Highlights Therapeutic Potential of Tizianas Foralumab 37

Jan 11, 2016: Tiziana announces plans for clinical development of foralumab, the company fully human CD3 antibody 38

Jun 28, 2011: MacroGenics Announces Publication Of Protege Phase III Clinical Data Of Teplizumab In The Lancet 38

Jun 23, 2011: MacroGenics To Present Protege Phase III Clinical Data Of Teplizumab In Type 1 Diabetes At ADA In San Diego, US 39

Mar 11, 2011: Tolerx And GSK Announce Phase III Defend-1 Study Of Otelixizumab In Type 1 Diabetes Fails Primary Endpoint 40

Oct 20, 2010: MacroGenics And Lilly Report Pivotal Clinical Trial Of Teplizumab Did Not Meet Primary Efficacy Endpoint 40

Sep 23, 2010: Tolerx Enrolls First Patient In Europe In DEFEND-2 Phase III Clinical Study For Treatment Of Type 1 Diabetes 41

Sep 23, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study At European Association For Study Of Diabetes Annual Meeting 42

Jun 28, 2010: Tolerx Initiates Confirmatory Phase III Trial With Otelixizumab For Type 1 Diabetes 43

Jun 28, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study Validating C-Peptide As Critical Clinical Measure For New-Onset Type 1 Diabetes 44

Mar 17, 2010: Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation Of Beta Cell Function 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by Amgen Inc, H2 2017 20

Pipeline by GlaxoSmithKline Plc, H2 2017 20

Pipeline by MacroGenics Inc, H2 2017 21

Pipeline by Numab Innovation AG, H2 2017 21

Pipeline by SYNIMMUNE GmbH, H2 2017 22

Pipeline by Tiziana Life Sciences Plc, H2 2017 22

Dormant Projects, H2 2017 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Amgen Inc

GlaxoSmithKline Plc

MacroGenics Inc

Numab Innovation AG

SYNIMMUNE GmbH

Tiziana Life Sciences Plc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person